ReviewEuropean journal of clinical pharmacology2013
Incidence, clinical features and management of hypersensitivity reactions to chemotherapeutic drugs in children with cancer.
Review in European journal of clinical pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 43 citations in OpenAlex.
- Breakthrough reactions in pediatric chemotherapeutic desensitization: Outcomes and associated risk factors.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Observational
- Etoposide Hypersensitivity Reactions in Pediatric Oncology: Understanding Mechanisms and Optimizing Management.Cancers · 2026Review
- Drug hypersensitivity reactions in children in clinical practice: A WAO Statement.The World Allergy Organization journal · 2025Review
- Platinum-induced ototoxicity and hearing impairment in children and adolescents.Drugs in context · 2025Review
- Standards for practical intravenous rapid drug desensitization & delabeling: A WAO committee statement.The World Allergy Organization journal · 2022Review
- Hidden Dangers: Recognizing Excipients as Potential Causes of Drug and Vaccine Hypersensitivity Reactions.The journal of allergy and clinical immunology. In practice · 2021Review
- Vincristine-Induced Peripheral Neuropathy (VIPN) in Pediatric Tumors: Mechanisms, Risk Factors, Strategies of Prevention and Treatment.International journal of molecular sciences · 2021Review
- Nanocarrier-Based Drug Delivery for Melanoma Therapeutics.International journal of molecular sciences · 2021Review
- Transdermal buprenorphine for pain management in children.Drugs in context · 2021Review
- Bone and Soft Tissue Sarcoma.Cancers · 2020Article
- Pediatric drug hypersensitivity: which diagnostic tests?Acta bio-medica : Atenei Parmensis · 2019Review
- Drug desensitization in allergic children.Acta bio-medica : Atenei Parmensis · 2019Review
- Methotrexate hypersensitivity reactions in pediatrics: Evaluation and management.Pediatric blood & cancer · 2017Article
- Rechallenge to Carboplatin in Children with Low Grade Glioma and Carboplatin Hypersensitivity Reactions.Frontiers in pharmacology · 2017Article
- Reactions related to asparaginase infusion in a 10-year retrospective cohort.Revista brasileira de hematologia e hemoterapiaArticle
- From the Children's Oncology Group: Evidence-Based Recommendations for PEG-Asparaginase Nurse Monitoring, Hypersensitivity Reaction Management, and Patient/Family Education.Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology NursesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHypersensitivity reactions (HSRs) may occur in children with cancer during the use of almost all chemotherapeutic drugs. HSRs may also produce a negative impact on treatment intensity and, as a consequence, worsen patients' outcome. The aim of this review is to summarize the incidence and the clinical features of HSRs occurring in children with cancer treated with chemotherapeutic drugs and their impact on treatment efficacy, in order to outline possible adequate prevention and management strategies.
methodsData were collected by searching for relevant studies about incidence, clinical features and management of hypersensitivity reactions that may occur with the use of chemotherapeutic agents in children aged 0-18 years, published from January 1976 to December 2012 in the PubMed database.
resultsIn children with cancer treated with chemotherapeutic drugs (especially platinum compounds, methotrexate, L-asparaginase), HSRs commonly present with mild/moderate to severe clinical patterns. Multiple factors appear to affect reaction rates, including route, rate of administration, previous exposure, drug form, presence of excipients. The occurrence of hypersensitivity to a chemotherapeutic agent can include the avoidance of re-exposure. For sensitized patients who have derived clinically meaningful benefit from a particular agent, however, continuation of treatment with the agent is desirable. Options may include attempting a trial of desensitization or treatment with a related compound.
conclusionsWith the increasing use of cancer chemotherapy agents, hypersensitivity reactions to antineoplastic drugs are commonly encountered. Clinicians must not underestimate the potential risk and occurrence of HSRs in the pediatric population. Knowledge of the different presentations of these reactions can help to develop strategies for the prevention and the management of HSRs in order to ensure treatment outcome, to improve the quality of patient care and to reduce healthcare costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.